Biblio

Found 5 results
Filters: Author is Aggarwal, Rahul Raj  [Clear All Filters]
2018
R. Raj Aggarwal, Lloyd, P., Huang, J., Beer, T. M., Zhang, L., Thomas, G. V., True, L. D., Alumkal, J. J., Friedl, V., Weinstein, A., and , “DNA repair mutations and treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC) as hallmarks of distinct subgroups of metastatic castration resistant prostate cancer (mCRPC): Data from the West Coast Prostate Cancer Dream Team.”. American Society of Clinical Oncology, 2018.
2016
E. Jay Small, Aggarwal, R. Raj, Huang, J., Sokolov, A., Zhang, L., Alumkal, J. J., Youngren, J., Ryan, C. J., Foye, A., Reiter, R. Evan, and , “Clinical and genomic characterization of metastatic small cell/neuroendocrine prostate cancer (SCNC) and intermediate atypical prostate cancer (IAC): Results from the SU2C/PCF/AACRWest Coast Prostate Cancer Dream Team (WCDT).”. American Society of Clinical Oncology, 2016.
R. Raj Aggarwal, Youngren, J., Sokolov, A., Huang, J., Thomas, G. V., True, L. D., Foye, A., Alumkal, J. J., Ryan, C. J., Beer, T. M., and , “Persistence of AR signaling in small cell neuroendocrine prostate cancer (SCNC) and intermediate atypical carcinoma (IAC): Results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT).”. American Society of Clinical Oncology, 2016.
2015
R. Raj Aggarwal, Thomas, G., Youngren, J., Foye, A., Olson, S., Paris, P., Beer, T. M., Ryan, C. J., Witte, O., Evans, C. P., and , “Androgen receptor (AR) amplification in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) and enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WC”. American Society of Clinical Oncology, 2015.
E. Jay Small, Huang, J., Youngren, J., Sokolov, A., Aggarwal, R. Raj, Thomas, G., True, L. D., Zhang, L., Foye, A., Alumkal, J. J., and , “Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): Preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer ”. American Society of Clinical Oncology, 2015.